Cell Therapy in Burn Repair

Laleh Khodadadi, M.Sc.1, Saeed Shafieyan, M.D.1, Nasser Aghdami, M.D., Ph.D.1 *, Hossein Baharvand, Ph.D.1, 2 *

1. Stem Cells Department, Cell Sciences Research Center, Royan Institute, ACECR, Tehran, Iran
2. Developmental Biology Department, University of Science and Culture, ACECR, Tehran, Iran

* Corresponding Addresses: P.O. Box: 19395-4644, Stem Cells Department, Cell Sciences Research Center, Royan Institute, ACECR, Tehran, Iran
Email: Nasser.Aghdami@royaninstitute.org
Email: Baharvand@royaninstitute.org

Abstract
Received: 16/Mar/2008, Accepted: 3/May/2008
Skin replacement has been a challenging task in wound healing resulted from burn. The application of laboratory based tissue expansion techniques is a potential solution to the problem of surface area cover. Fortunately, considerable progress has been made in approaches to allograft and autograft skin transplantation in order to replace skin temporarily or permanently. Despite of this progress, development of new treatments for burn victims are still a problem in cultured skin grafts. Hair follicles, sweat glands and other features of normal skin are absent in cultured skin. Scientists believe that Stem cells with unique characteristics including self renewal and differentiation potential offer a possible way for reconstruction of some structures within the wound. So, enhanced understanding of stem cell potentials may help develop novel therapies to overcome the problems in wound healing.

Keywords: Burn, Cell Therapy, Skin Transplantation, Stem Cells

Introduction
Burns are one of the most common and devastating forms of trauma. Patients with serious thermal injury require immediate specialized care in order to minimize morbidity and mortality. A report of the National Center for Injury Prevention and Control in the United States shows approximately 1.2 million people affected with burn injuries (1). Burn injuries in Iran, like other developing countries, are much more common than in the USA. Moreover, the mean age of Iranian patients is less than others, and the mortality rate is higher. In recent epidemiology study in Tokyo, the overall mortality rate was 15.4%, whereas this rate in Shiraz was 32% (2).

The choice between tissue repair or replacement method in acute or chronic loss of skin barrier needs information about burn severity and involved skin layers determination (3). Several factors are used to determine the severity of a burn injury, including the patient’s age, size and depth of burn, and the location of the burn. Burns are classified by depth and they may be first, second, or third degree which sometimes known as superficial, partial thickness, or full-thickness, respectively (4). First degree burns (Superficial Burns) involve minimal tissue damage and they involve only the superficial layer of skin (epidermis). This type of burn usually heals in 5-6 days without any permanent scarring. Second-degree burns (Partial-Thickness Burns) affect both the outer-layer (epidermis) and the underlying layer of skin (dermis) causing redness, pain, swelling and blisters. This type of burn usually heals in 3-4 weeks, and scar formation may occur. Third-degree burns (Full-Thickness Burns) affect the epidermis, dermis and hypodermis; causing charring of skin, or translucent white coagulated vessels visible just below the skin surface. This type of burn can be extremely painful or relatively painless if the burn destroys the nerve endings. This burn is critical and requires immediate medical attention. Loss of the functional skin barrier leads to increase susceptibility to infection, the major cause of morbidity and mortality following burns. Skin is the body’s largest organ. Its structure has been designed in a way that functions as the first line of defense protecting against the invasion of foreign bodies and organisms. It has specific immune and metabolic functions and is important in regulating body temperature, fluid and electrolytes (3). Skin contains the three main layers of the most superficial epidermal barrier layer and the lower, much thicker, dermis and the deepest, hypodermis or fat layer. The epidermal barrier layer is relatively thin (0.1-0.2 mm in depth) and the most common cells in the epidermis are keratinocytes that form the surface barrier layer. The dermis varies in thickness depending on its site in the body; composing primarily of collagen I, dermal inclusions of hair shafts, and sweat glands; which are lined with epidermal keratinocytes. Fibroblasts form the lower dermal layer and provide strength and resilience (5).

A number of approaches were taken in burn repair. One way is skin grafting. Advantages of graft-take to wound healing include an immediate barrier to microorganism...
invasion and minimal new tissue synthesis required to close the defect. The take of a skin graft requires minimal new tissue synthesis (6). Other approaches are the developing of skin substitutes such as an acellular matrix complex that would guide the migration of fibroblasts into a pattern that had dermal-like qualities (7). Another way is to expand a small piece of epidermis into a very large transplantable viable autologous-epidermal cell layer through tissue culturing (8). The new method is to develop a skin equivalent composed of both a collagen matrix populated with viable fibroblasts and a dermal equivalent layer that is covered with viable keratinocytes (epidermal layer) (9). This skin equivalent have both a connective tissue component and viable cells (6). However, methods for handling burn wounds have changed in recent decades like: transplantation, tissue engineering and now, stem cells therapies. But, questions related to optimal cell type for culture, culture techniques, transplantation of confluent sheets or non-confluent cells, immediate and late final take, carrier and transfer modality, as well as final outcome, ability to generate an epithelium after transplantation, and scar quality are still not fully answered. In this review article, we are going to mention the current and promising cell therapy methods to burn repair.

**Skin grafts**

There are a variety of skin grafts, some that provide temporary cover and others that are for permanent wound coverage.

**Allogenic skin graft (Temporary Wound Covering)**

Allogeneic or alloplastic skin substitute coverage as a temporary solution is necessary until definitive cover can be achieved (10-18). The clinical use of allograft skin in the modern era was popularized by James Barrett Brown, who described its use in 1942. Skin grafting, which consists of excision or the surgical removal of burn injured tissue; choosing a donor site or an area from which healthy skin is removed to be used as cover for the cleaned burned area; and harvesting, where the graft is removed from the donor site by a dermatome that shaves a piece of skin, about 10/1000 of an inch thick, off the unburned area. Finally, the surgeon places and secures the skin graft over the surgically cleaned wound so that it can heal. To help the graft heal and become secure, the area of the graft is not moved for five days following each surgery (immobilization period). During this immobilization period, blood vessels begin to grow from the tissue below into the donor skin, bonding the two layers together. Five days after grafting, exercise therapy programs, tub baths and other normal daily activities resume (19). Allogenic skin grafts may be completely integrated into the healing wound initially and bridge the critical time gap in the early phase of burn treatment.

However, the need to provide skin cover in a situation of inadequate donor sites lead to the interest in cultur-
skin to cover a larger body surface area. Meshing is a mean to enlarge donor skin. Meshing involves running the donor skin through a machine that makes small slits, which allows expansion similar to that in fish netting. In a meshed skin graft, the skin from the donor site is stretched to allow it to cover an area larger than itself. Most donor skin is meshed at a 1:1 or 1:2 ratio because the larger the size mesh the more fragile the graft. No matter what size meshing is used; healing occurs as the spaces between the mesh; called the intricities, fill in with new epithelial skin growth. The disadvantages of meshing are to be a less durable graft than a sheet graft. Meshing serves two purposes: it allows blood and body fluids to drain from under the skin grafts, preventing graft loss, and it allows the donor skin to cover a greater burned area because it is expanded (19).

Fig 1: A 10-month-old baby girl. A) Seven days after grafting cryopreserved cultured epidermal allografts on the recipient site of the back. Inside the arrow heads shows the area where the grafts were taken. B) One month after grafting. The grafted area has milder redness compared to the non-grafted area. C) Seven months after grafting. The grafted area has less scar formation compared to the non-grafted area. D) Thirty-nine months after grafting. Scar formation was clearly suppressed on the grafted area. Inside the arrow heads shows the grafted area. Adopted from (29).

Fig 2: The main cells of skin. A) Keratinocytes; are the most common cell type in the epidermis and form the surface barrier layer. B) Melanocytes; are found in the lower layer of the epidermis and provide skin color. C) Fibroblasts form the lower dermal layer and provide strength and resilience.
Cultured skin autograft
In massive burns, however, the available skin donor sites for autografting may be very limited. This has fostered the development of alternative methods such as autologous cultured skin graft and allograft skin substitutes as mentioned before. Two main techniques in autogenous graft for burn treatment include "cultured epithelial autografts; CEA" and "cell suspension".

Cell cultured epithelial autograft (CEA)
In 1975, Reinwald and Green demonstrated that disaggregated epidermal cells (Fig 2) could be isolated and serially sub-cultured in vitro (shown in Fig 3) (30). Shortly afterwards, viable epithelial sheets, suitable for grafting were produced. From 1981, clinical case reports describing the use of cultured keratinocytes as permanent autografts in burn wound management were published (31).

Cultured sheets of human autologous epithelium (CEA = cultured epithelial autografts) still represent the "gold standard" to resurface large wounds (8). So, cultured epidermal sheet autografts became available to complement autologous split thickness skin grafts in treating major burns or other large wounds (8).

Despite of more laboratory skills in producing confluent grafts of keratinocytes, the epidermal sheet grafts have several shortcomings (13, 33, 34). First, harvesting the cell sheets from the culture dishes by trypsin treatment could damage the anchoring proteins of the cells (35-37). This could be one of the reasons of a mechanical instability of epidermal sheet grafts and insufficient dermal–epidermal reconstitution that lowers the uptake ratio of the grafts for a long time after transplantation (36, 38, 39). Second, epidermal sheet grafts usually require a long fabrication period (40). Third, cultured epidermal sheet grafts composed of fully differentiated keratinocytes might not exhibit further proliferation of keratinocytes after transplantation (35). Fourth, epidermal sheets are only 8–10 cells thick, which make them fragile and difficult to handle (8, 36) and have high costs of production (37).

The attention to, and understanding of, these shortcomings have led to a progressive development of skin culture techniques and an increased use of suspensions of keratinocytes single cells being transplanted instead of sheet grafts.

Cell suspensions
Surprisingly good clinical results using the technique of "epithelial cell seeding" had been published by von Mangoldt as early as in 1895 to treat chronic wounds and wound cavities (41). In his original description he harvested epithelial cells or cell clusters by scraping off superficial epithelium from a patient's forearm with a surgical blade until fibrin was exuded from the wound. This mixture was then applied to wounds. He claimed reduced donor site morbidity and a more regular aspect of the resurfaced wounds when compared to the method of Reverdin, which was the common method at that time. One of his key observations was the fact that single cells or cell clusters would better attach to the wound bed than conventional pieces of skin.

One problem associated with pipetting keratinocytes in suspension is to prevent spillage of cells from the wound and achieve an even delivery (42). Fraulin et al. (43), in 1998, described a novel technique in which they used an aerosol device to spray epithelial cells on wounds in pigs. They noted that re-epithelialisation, re-growth of epithelial tissue over a denuded surface, was quicker than in unsprayed controls. Further advantages of suspension transplantation are to reduce time needed for culture and the fact that suspended keratinocytes can be transported from laboratory to patient in small vials, thus reducing the costs involved and storing frozen in clinic for transplantation (44). Because the cells, in culturing and transplanting, are as a suspension rather than a sheet; the use of enzymes like, Dispase1 can be avoided (45). Navarro et al. (46) developed this technique further by combining it with meshed split thickness skin grafts. They reported faster healing and a better quality of cells when they were sprayed.

Fig 3: Diagram showing the various steps of the classical keratinocyte culture technique described by Rheinwald and Green. Adopted by modification from (32).
A comparative in vitro study has been done by Fredriksson and et al. (44), considering commonly used application techniques. Although, it has not been compared in vivo with in vitro condition, it did provide valuable information about different measures in transplantation of autologous keratinocytes as a single cell suspension. There is hope that, with further studies, advances in this field will lead to the development of an equipment that is fairly cheap and easy to operate (44).

However, an alternative approach to facilitate the delivery of keratinocytes in suspension is to use a matrix material such as fibrin glue to fix the cells (47).

Membrane delivery systems
To transfer preconfluent keratinocytes to a wound, a delivery system is required. Various methods have been described. Cells can be grown in a culture vessel, trypsinized, and applied directly in suspension or grown directly onto a delivery membrane that is then removed from the dish, inverted, and applied to the wound bed.

A number of delivery systems based on biological tissue including Collagen I (48-51), Fibrin Glue, a human plasma protein concentrate that contains fibrinogen, factor XIII, and fibronectin that have undergone viral inactivation (52, 53), Hyaluronic Acid (54), Acellular Porcine Dermis (55) or based on synthetic polymers such as Polyurethane (56), Polymeric Film (57), Teflon® Film (58), Poly(hydroxyethyl Methacrylate) (59), Celltrian (60), Spherical Microcarriers (61) have been developed (review in (56). Membrane delivery systems have the advantage of easy handling and ensuring contact of cells with the wound. The potential disadvantages are that a proportion of keratinocytes may not attach to the membrane, and of those that do attach, not all will transfer to the wound bed (56). These potential inefficiencies need to be assessed for each delivery method. However, it is difficult to compare the efficacy of the delivery systems because of variations in used keratinocyte seeding density and studied types of wound.

Moreover, these delivery methods only transfer keratinocytes and are only part of the solution to wound coverage after full-thickness skin loss in burns patients. It is widely appreciated that the addition of a dermal substitute to such a wound is important for stable wound healing (62-65). This may also require the transplantation of fibroblasts to enhance healing further and improve the mechanical properties of the graft (66-68). The role of delivery of preconfluent keratinocytes in conjunction with methods of dermal delivery should also be assessed.

Table 1: Current commercially available or marketed matrices and products for tissue engineered skin substitutes. Adopted from (41).

<table>
<thead>
<tr>
<th>Material</th>
<th>Brand Name</th>
<th>Manufacture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen gel + cult. Allog. HuK + allog. HuFi</td>
<td>Apligraft™ (earlier name: Graftskin™)</td>
<td>Organogenesis, Canton, MA</td>
</tr>
<tr>
<td>cult. Autol HuK</td>
<td>Epicell™</td>
<td>Genzyme Biosurgery, Cambridge, MA</td>
</tr>
<tr>
<td>PGA/PLA + ECMP DAHF</td>
<td>Transcyte™</td>
<td>Advanced Tissue LaJolla, CA</td>
</tr>
<tr>
<td>Collagen GAG silicone foil</td>
<td>Integra™</td>
<td>Integra LifeScience, Plainsborough, NJ</td>
</tr>
<tr>
<td>Acellular dermis</td>
<td>AlloDerm™</td>
<td>Lifecell Corporation, Branchberg, NJ</td>
</tr>
<tr>
<td>HAM + cult. HuK</td>
<td>Laserskin™</td>
<td>Fidia Advanced Biopolymers, Padua, Italy</td>
</tr>
<tr>
<td>PGA/PLA + allog. HuFi</td>
<td>Dermagraft™</td>
<td>Advanced Tissue Sciences, LaJolla, CA</td>
</tr>
<tr>
<td>Collagen + allog HuFi + allog HuK</td>
<td>Orcelet™</td>
<td>Ortec International, Inc., New York, NY</td>
</tr>
<tr>
<td>Fibrin sealant + cult. Autol HuK</td>
<td>Bioseed™</td>
<td>BioTissue Technologies, Freiburg, Germany</td>
</tr>
<tr>
<td>PEO/PBT + autol. HuFi + cult autol HuK</td>
<td>Polyactive™</td>
<td>HC Implants</td>
</tr>
<tr>
<td>HAM + HuFi</td>
<td>Hyalograft 3D™</td>
<td>Fidia Advanced Biopolymers, Padua, Italy</td>
</tr>
<tr>
<td>Silicone + nylon mesh + collagen</td>
<td>Biobrane™</td>
<td>Pharmac., Sugar Land, TX</td>
</tr>
</tbody>
</table>

ECMP = extracellular matrix proteins, DAHF = derived from allog. HuFi, GAG = glycosaminoglycan, PGA = polyglycolic acid (Dexon™), PLA = polylactic acid (Vicryl™), PEO = polyethylene oxide, PBT = polybutylterephthalate, cult. = cultured; autol. = autologous, allog. = allogeneic, HuFi = human fibroblasts, HuK = human keratinocytes, HAM = microperforated Hyaluronic Acid Membrane (benzilic esters of hyaluronic acid = HYAFF-11®)
At the moment, scientific principles and practical approaches to replace skin temporarily or permanently are advancing at a rapid rate. However, there is definitely need further progress to optimize skin substitute performance by tissue engineering procedures.

**Skin tissue engineering**

The skin is indeed a complex structure incorporating a fusion of several different cell types, integrated within a three dimensional matrix containing both fibrillar and nonfibrillar elements. To synthesize such a complex structure by identifying the component parts and to put them together is neither practical nor realistic. It must be observed, however, that this integrative strategy has been the major one used in skin tissue engineering during its less productive phase (69).

Three factors should be considered in the development of tissue-engineered materials: the safety of the patient, clinical efficacy and convenience of use. Any cultured cell material carries the risk of transmitting viral or bacterial infection, and some support materials (such as bovine collagen and murine feeder cells) may also have a disease risk. There must be clear evidence that tissue-engineered materials provide benefit to the patient. Essential characteristics are that it heals well and has the physical properties of normal skin. To achieve effective healing, the tissue-engineered products must attach well to the wound bed, be supported by new vasculature, not be rejected by the immune system and be capable of self repair throughout a patient’s life. Finally, materials need to be convenient to use or they will not achieve clinical uptake (5).

Most tissue-engineered skin is created by expanding skin cells in the laboratory (at a rate much greater than would be achieved on the patient) and used to restore barrier function (the primary objective for burns patients) or to initiate wound healing (for chronic non-healing ulcers). Currently, commercially available or marketed matrices and products for tissue engineered skin substitutes are shown in Table 1. There are those that replace the epidermal layer only, those that provide a dermal substitute, and a small number that provide both. In some clinical conditions (such as non-healing ulcers and superficial burns) simply transferring laboratory-expanded cells can benefit patients, but the treatment of major full-thickness burns requires the replacement of both dermis and epidermis. There are four major challenges in this field: improving safety, finding a substitute for split-thickness grafts, improving angiogenesis in replacement tissue once it has been grafted to the wound bed, and improving ease of use (5). Fig 4 shows the ‘biological’ as opposed to the ‘engineering’ concepts of the skin structure.

Although progress has been made in developing new treatments for burn victims, including skin grafting and artificial skin technologies; these cultured skin grafts do not have hair follicles, sweat glands and other features of normal skin. The result is thin, inflexible skin (which hampers mobility of joints), and skin that dramatically differs from the remaining healthy skin. A promising alternative to these techniques is stem cell-based therapy. Scientists believe that results of stem cell research will help identify those cells responsible for differentiating into the various elements that comprise the dermis, and eventually produce skin that will help patients heal quicker with less scarring and more flexibility, and perhaps, even produce a skin that literally matches that of the rest of the body.

**Stem cell strategies in burn care**

Stem cells are characterized by their prolonged self-renewal capacity and their asymmetric replication (70) (Fig 5). Asymmetric replication describes a special property of stem cells: with every cell division, one of the cells retain its self-renewing capacity, whereas the other enter a differentiation pathway and join a mature non-dividing population (71). Stem cells were first identified as pluripotent cells in embryos, and these were called embryonic stem (ES) cells which are defined by
It is now clear that stem cells are also present in many, if not all, tissues in adult animals and contribute to the maintenance of tissue renewal and homeostasis. Currently, the challenge is to define the optimum source; processing and method of application of stem cells as well as defining their role.

It has been known for several decades that the epidermis of the skin contains a subpopulation of basal cells that exhibit the properties expected of somatic stem cells: slow cell cycle, high proliferative potential, location in a protected niche, capacity to maintain and repair the tissue in which they reside, and long life span (Fig 6) (73-77). Slowly, cycling epidermal stem cells have been identified by long-term nuclear retention of tritiated thymidine or bromodeoxyuridine label (74, 78). These undifferentiated label-retaining stem cells have been shown to reside in the bulge area of the hair follicle, (76, 79, 80) and in the interfollicular basal layer of the epidermis (74, 78, 81). They are self-renewing and able to produce daughter transient amplifying cells that undergo a finite number of cell divisions before they differentiate and leave the proliferative basal compartment, a property similar to stem cells in other continuously renewing tissues (82). Scientists have found that skin progenitor stem cells (keratinocyte progenitors) in adult human skin have a significant capacity for growth and tissue regeneration.

Stem cells can be induced to differentiate into cells with specialized functions, such as skin keratinocytes (84). It is for this reason that stem cells show such potential for treating burns. But what type of stem cell shows the most applicable? The clinical application of embryonic stem cells is likely to be beset with numerous ethical but also safety concerns. Fetal tissue, likewise, will be associated with ethical issues. The reality of widespread applications of stem cells devoid of complex ethical dimensions really begins with human umbilical cord blood and Bone-marrow derived stem cells. This has been used in a number of clinical ‘haematopoietic’ applications as a ‘transplant’ which underlines the safety and efficacy of these stem cell sources (85-87).

There are two main branches of stem cells in the bone marrow (BM), hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) (Fig 7). Adult bone marrow-derived HSCs have long been recognized to give rise to all blood cell lineages and some non-blood cells such as hepatocytes, (88) endothelial cells (EC), smooth muscle cells, and cardiac myocytes (89). However; much controversy exists over HSC plasticity. In contrast, BM-MSCs are self-renewing, clonal precursors of non-hematopoietic tissues. Although they are present as a rare population of cells in bone marrow, representing perhaps 0.001–0.01% of the nucleated cells and about 10-fold less abundant than HSCs; they are expandable in culture, multipotent, and capable of differentiating into osteoblasts, chondrocytes, astrocytes, pneumocytes, hepatocytes, neurons, and cardiac myocytes (89-95). As Bone Marrow derived Cells (BMDCs) have been found in skin epidermis in several studies (96-100),
it is assumed that Bone Marrow Stem Cells (BMSCs) may be involved in skin repair and regeneration. The most studied progenitor cell type is the hematopoietic stem cell (HSC) from the bone marrow. By creating chimeric mice that express green fluorescent protein (GFP) only in their bone marrow cells; Hocking and et al (96) have found that HSCs migrate to sites of dermal injury, differentiate into several cell phenotypes, and incorporate into the cutaneous wound for the long term. The majority of these bone marrow derived cells resemble undifferentiated dermal fibroblasts with occasional dendritic type cells and endothelial cells. These findings suggest that bone marrow derived cells in the wound, not only participate in the inflammatory response, but are an important source of cells for reconstituting the dermis.

MSCs seem to be non immunogenic and maybe “universal”(101). They can confer a state of immune tolerance to the recipient (97-100). If this is true, a new era of understanding will be started in Transplantation. But, why should a cell have evolved in such a way to be involved both in regeneration and tolerance? Burn patients have transient states of immune suppression and acceptance of allografts in the acute phase in parallel with their increased pool of circulating MSCs (101, 102). Direct injection of bone marrow derived mesenchymal stem cells or endothelial progenitor cells into injured tissues shows improved repair through mechanisms of differentiation and/or release of paracrine factors (70). Previous studies have shown that cultured Epithelial Cells(EPCs) release growth factors, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor, G-CSF, GM-CSF, and platelet-derived growth factor-B61 that could exert a protective effect on endogenous EC and other myocardial cells. Cultured BM-MSCs have been found to release VEGF, basic fibroblast growth factor (bFGF), IL-6, placental growth factor (PIGF), and monocyte chemoattractant protein-1 (103).

Could MSCs be the link between this state of tolerance and the capacity to regenerate? If it is to be proved, the new field of Regenerative Medicine, Transplantation and Burns beside many other disciplines will profoundly benefit from these discoveries without any doubt. In fact, Han et al (104), have been shown that Burn rat serum has a stronger chemotactic effect on MSCs and the migration ability of MSC derived from burn rat is stronger than that of MSC derived from normal rat.

The prospect of being able to replace damaged tissue by the process of regeneration would dramatically and irrevocably change the impact, management and outcome of burns. The current understanding of stem cell-based modulation and therapy together with their potential developments bring this prospect ever closer to a clinical reality. Despite of the potential surrounding the stem cell field, we remain a long way from translating the research now being conducted in laboratories to therapies for patient.

Conclusion & Future outlook

Burns are one of the most harmful and complex physical injuries. They often happen unexpectedly and have the potential to cause death, lifelong disfigurement and dysfunction. The challenge of surviving a major burn depends on skin repair. Recently, skin grafting has evolved from the initial autograft and allograft preparations to biosynthetic and tissue-engineered living skin replacements. Tissue engineering now provides the clinician with more therapeutic options and more challenges. Consequently, it is essential to critically analyze the clinical needs of skin repair and understand skin replacement in terms of the availability, compatibility, safety and durability. However both through basic and clinical research, there will be major improvements in the understanding and ability to effectively deal with the problems of wound healing and replace a truly functional skin with dermal appendages. Research on stem cells may lead to improve skin reconstitution, while overcoming current limits of donor sites and donor site morbidity in afflicted patients.
References

23. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K. Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. Immunology, 1989; 68(1): 31-36
33. Munster AM. Whither (corrected) skin replacement? Burns, 1997; 23(1)
on a microspherical transport system are feasible to reconstitute the epidermis in full-thickness wounds. Tissue Eng, 1999; 5(6): 563-572


60. Rouabia M. Permanent skin replacement using chimeric epithelial cultured sheets comprising xenogeneic and syngeneic keratinocytes. Transplantation, 1996; 61(9): 1290-1300


104. Han B, Fu XB, Han B, Lei YH, Chen W, Sun TZ. Chemotactic effects of burn rat serum on mesenchymal stem cells derived from different sources. Zhonghua Shao Shang Za Zhi, 2007; 23(1): 25-28